SalioGen
Financing Rounds
- Series B
- Exit
Round Led or Co-led By SymBiosis
Round Led or Co-led By SymBiosis
SalioGen Therapeutics has launched Gene CodingTM, a genetic medicine platform, to develop durable, broadly applicable genetic medicines, using its Exact DNA Integration Technology™ (EDIT™) platform. EDIT is based on the novel mammal-derived genomic engineering tool, for use in potentially curative genetic medicines. SalioGen is focused on developing therapies for more patients with inherited diseases that are beyond what is addressable with current technologies, initially focusing on inherited macular disorders and inherited lipid disorders.
Modality
- Genetic Medicine
Indications
- Oncology
- Other
Development Status
- Pre-Clinical